Constitutively activated Cdc42 enhances cardiomyocyte hypertrophy, and downregulated or inhibited Cdc42 activity attenuates LIF-induced cardiomyocyte elongation or high salt-induced cardiac hypertrophy and fibrosis [13, 27]. The gene discussed is LIF; the disease is cardiac hypertrophy.